The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells
Abstract
Tumor cells secreting IL-1β are invasive and metastatic, more than the parental line or control mock-transfected cells, and concomitantly induce in mice general immune suppression of T cell responses. Suppression strongly correlates with accumulation in the peripheral blood and spleen of CD11b+/Gr-1+ immature myeloid cells and hematological alterations, such as splenomegaly, leukocytosis, and anemia. Resection of large tumors of IL-1β-secreting cells restored immune reactivity and hematological alterations within 7–10 days. Treatment of tumor-bearing mice with the physiological inhibitor of IL-1, the IL-1R antagonist, reduced tumor growth and attenuated the hematological alterations. Depletion of CD11b+/Gr-1+ immature myeloid cells from splenocytes of tumor-bearing mice abrogated suppression. Despite tumor-mediated suppression, resection of large tumors of IL-1β-secreting cells, followed by a challenge with the wild-type parental cells, induced resistance in mice; protection was not observed in mice bearing tumors of mock-transfected fibrosarcoma cells. Altogether, we show in this study that tumor-derived IL-1β, in addition to its proinflammatory effects on tumor invasiveness, induces in the host hematological alterations and tumor-mediated suppression. Furthermore, the antitumor effectiveness of the IL-1R antagonist was also shown to encompass restoration of hematological alterations, in addition to its favorable effects on tumor invasiveness and angiogenesis that have previously been described by us.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationMechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
IL-1 is required for tumor invasiveness and angiogenesis
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C. A., & Apte, R. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437939100 · Cited by 1,023
Self-citationMechanisms of suppression by suppressor T cells
von Boehmer, H. (2005) · Nature Immunology · doi:10.1038/ni1180 · Cited by 1,007
Going both ways: Immune regulation via CD1d-dependent NKT cells
Godfrey, D. I., & Kronenberg, M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200423594 · Cited by 877
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
The balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
The IL-1 family and inflammatory diseases.
Dinarello, C. A. (2002) · PubMed · Cited by 599
Self-citationζ Phosphorylation Without ZAP-70 Activation Induced by TCR Antagonists or Partial Agonists
Madrenas, J., Wange, R. L., Wang, J. L., Isakov, N., Samelson, L. E., & Germain, R. N. (1995) · Science · doi:10.1126/science.7824949 · Cited by 505
Blocking IL-1 in systemic inflammation
Dinarello, C. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050640 · Cited by 494
Self-citationPiccirillo, C. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2003.12.003 · Cited by 392
Interleukin 1 is a radioprotector.
Neta, R., Douches, S., & Oppenheim, J. J. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2483 · Cited by 371
TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response
Baniyash, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1434 · Cited by 344
Derangement of immune responses by myeloid suppressor cells
Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., & Bronte, V. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0443-2 · Cited by 335
Bronte, V., Wang, M., Overwijk, W. W., Surman, D. R., Pericle, F., Rosenberg, S. A., & Restifo, N. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5313 · Cited by 312
Mantovani, A., Allavena, P., & Sica, A. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.03.016 · Cited by 311
Immature myeloid cells and cancer-associated immune suppression
Kusmartsev, S., & Gabrilovich, D. I. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297
Melani, C., Chiodoni, C., Forni, G., & Colombo, M. P. (2003) · Blood · doi:10.1182/blood-2003-01-0190 · Cited by 295
NKT cells — conductors of tumor immunity?
Smyth, M. J., Crowe, N. Y., Hayakawa, Y., Takeda, K., Yagita, H., & Godfrey, D. I. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00316-3 · Cited by 294
Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1.
Mochizuki, D. Y., Eisenman, J. R., Conlon, P. J., Larsen, A. D., & Tushinski, R. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.15.5267 · Cited by 289
Immunoregulatory T cells in tumor immunity
Terabe, M., & Berzofsky, J. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.010 · Cited by 264
Interleukin-1—a major pleiotropic cytokine in tumor–host interactions
Apte, R. N., & Voronov, E. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00014-7 · Cited by 212
Self-citationAlterations in T cell receptor and signal transduction molecules in melanoma patients.
Zea, A. H., Curti, B. D., Longo, D. L., Alvord, W. G., Strobl, S., Mizoguchi, H., Creekmore, S. P., O’Shea, J. J., Powers, G. C., & Urba, W. J. (1995) · PubMed · Cited by 190
Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness
Song, X., Voronov, E., Dvorkin, T., Fima, E., Cagnano, E., Benharroch, D., Shendler, Y., Bjorkdahl, O., Segal, S., Dinarello, C. A., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6448 · Cited by 169
Self-citationImmortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes
Apolloni, E., Bronte, V., Mazzoni, A., Serafini, P., Cabrelle, A., Segal, D. M., Young, H. A., & Zanovello, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6723 · Cited by 157
Down-regulation of ?-chain expression in T cells: a biomarker of prognosis in cancer?
Whiteside, T. L. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0521-0 · Cited by 151
Atochina, O., Daly‐Engel, T. S., Piskorska, D., McGuire, E., & Harn, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4293 · Cited by 144
Resection of Solid Tumors Reverses T Cell Defects and Restores Protective Immunity
Salvadori, S., Martinelli, G. P., & Zier, K. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2214 · Cited by 144
Rambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A., Dinarello, C., & Cozzolino, F. (1991) · Blood · doi:10.1182/blood.v78.12.3248.3248 · Cited by 129
Self-citationLiu, Y., Ginderachter, J. A. V., Brys, L., BAETSELIER, P. D., Raes, G., & Geldhof, A. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5064 · Cited by 104
Bar, D., Apte, R. N., Voronov, E., Dinarello, C. A., & Cohen, S. (2003) · The FASEB Journal · doi:10.1096/fj.03-0483fje · Cited by 98
Self-citationSuperantigen-Induced CD4 T Cell Tolerance Mediated by Myeloid Cells and IFN-γ
Cauley, L. S., Miller, E., Yen, M., & Swain, S. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6056 · Cited by 87
Douvdevani, A., Huleihel, M., Zöller, M., Segal, S., & Apte, R. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510526 · Cited by 73
Self-citationRegulation of antitumour immunity by CD1d-restricted NKT cells
Swann, J. B., Crowe, N. Y., Hayakawa, Y., Godfrey, D. I., & Smyth, M. J. (2004) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2004.01254.x · Cited by 66
Voronov, E., Weinstein, Y., Benharroch, D., Cagnano, E., Ofir, R., Dobkin, M., White, R. M., Zöller, M., Barak, V., Segal, S., et al. (1999) · PubMed · Cited by 51
Self-citationHacham, M., Argov, S., White, R. M., Segal, S., & Apte, R. N. (2002) · PubMed · Cited by 51
Self-citationSeo, N., Hayakawa, S., & TOKURA, Y. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00015-9 · Cited by 42
Apte, R. N., Douvdevani, A., Zöller, M., White, R. M., Dvorkin, T., Shimoni, N., Fima, E., Hacham, M., Huleihel, M., Benharroch, D., et al. (1993) · Immunology Letters · doi:10.1016/0165-2478(93)90163-v · Cited by 35
Self-citationHuleihel, M., Douvdevani, A., Segal, S., & Apte, R. N. (1993) · Cytokine · doi:10.1016/1043-4666(93)90023-x · Cited by 34
Self-citationSchirò, R., Longoni, D. V., Rossi, V., Maglia, O., Doni, A., Arsura, M., Carrara, G., Masera, G., Vannier, E. G., & Dinarello, C. A. (1994) · Blood · doi:10.1182/blood.v83.2.460.460 · Cited by 30
Self-citationZöller, M., Douvdevani, A., Segal, S., & Apte, R. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500321 · Cited by 29
Self-citationInterleukin‐1 produced by tumorigenic fibroblasts influences tumor rejection
Zöller, M., Doudevani, A., Segal, S., & Apte, R. N. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500320 · Cited by 26
Self-citationBjörkdahl, O., Dohlsten, M., & Sjögren, H. O. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700248 · Cited by 23
Interleukin-1, stromal cells, granulopoiesis, and the inflammatory response
Bagby, G. C. (1989) · Biotherapy · doi:10.1007/bf02171001 · Cited by 6
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
Wroblewski, L. E., Peek, R. M., & Wilson, K. T. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00011-10 · Cited by 1,442
Metadata
- Authors
- Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., Voronov, E., & Apte, R. N.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12
- Volume
- 175
- Issue
- 12
- Pages
- 8200-8208
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2126889178
- Cited by
- 290
- References
- 45
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.